HARRISBURG, Pa., June 25 /PRNewswire/ -- In a revolutionary healthcare finding, a peer-reviewed clinical study published in the British Journal of Nutrition (a Cambridge University Journal), clearly shows that Prebiotics reduce cholesterol and triglycerides, control body weight, and increase lifespan by 33%.
The controlled clinical study was conducted on rats and showed that the rats fed prebiotics had an 80% survival rate to 24 months versus a 50% survival rate for the control group rats that were not fed prebiotics. Additionally, the "prebiotic" rats showed material reductions in cholesterol and body weight versus the control group.
Significantly, the prebiotic used in the study was oligofructose enriched inulin, a blend of two prebiotics which has repeatedly shown synergistic health benefits versus the more common single-prebiotic fibers such as plain inulin.
"This study, clearly demonstrating life-lengthening impact of prebiotics, has truly profound implications," says Jackson GI Medical CEO Kristian Chronister. "It certainly reinforces our commitment to powering our Prebiotin prebiotic supplements with oligofructose enriched inulin despite the dramatically lower cost of plain inulin," he says.
Oligofructose enriched inulin is a 100% natural, plant-derived 'compound' prebiotic fiber which has extensive clinical research demonstrating strong health benefits. Plain inulin is a far cheaper prebiotic which is used in most prebiotic supplements and enhanced foods.
"The implications of this study are somewhat staggering," says Jackson GI Chairman and Founder Frank W. Jackson, M.D. "While the research doesn't quite yet justify a claim that Page: 1 2 Related medicine technology :1
. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2
. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer3
. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain4
. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma5
. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor6
. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-7967
. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD8
. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study9
. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression10
. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus11
. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes